Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China
PR Newswire•29/10/2026•07:30 ET
0
Key Highlights
- ➤Three non-exclusive distributors appointed across six mainland China markets
- ➤Initial product focus: ELISpot plates and antigen-specific peptide pools
- ➤Agreements build on initial China sales and extend distributor-led strategy
- ➤Virax provides supply, documentation and technical support while distributors manage resale
- ➤China expansion targets biotechnology and academic research customers without larger direct-sales buildout
Expert Statements
James Foster, Chairman and Chief Executive Officer of Virax Biolabs
“China represents an important opportunity for ImmuneSelect, with substantial biotechnology and academic research activity in cellular immunology, vaccine development and infectious diseases”
James Foster, Chairman and Chief Executive Officer of Virax Biolabs
“These appointments allow us to reach prospective customers through established local distribution networks, with the objective of converting product evaluations into orders and building recurring reagent sales.”
James Foster, Chairman and Chief Executive Officer of Virax Biolabs
“Importantly, we can pursue that opportunity while maintaining a disciplined, capital-efficient commercial model.”
Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China PR Newswire
Three new distributor agreements build on initial China sales and extend the Company's distributor-led commercial strategy
Get started
Create a free account to read the full story.